Cargando…
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Although the landscape for treating acute myeloid leukemia (AML) patients has changed substantially in recent years, the majority of patients will eventually relapse and succumb to their disease. Allogeneic stem cell transplantation provides the best anti-AML treatment strategy, but is only suitable...
Autores principales: | Nixdorf, D., Sponheimer, M., Berghammer, D., Engert, F., Bader, U., Philipp, N., Kazerani, M., Straub, T., Rohrbacher, L., Wange, L., Dapa, S., Atar, D., Seitz, C. M., Brandstetter, K., Linder, A., von Bergwelt, M., Leonhardt, H., Mittelstaet, J., Kaiser, A., Bücklein, V., Subklewe, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244166/ https://www.ncbi.nlm.nih.gov/pubmed/37106163 http://dx.doi.org/10.1038/s41375-023-01905-0 |
Ejemplares similares
-
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022) -
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021) -
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
por: Köhnke, Thomas, et al.
Publicado: (2022) -
CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023) -
Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)